Evolus, Inc. (NASDAQ: EOLS) is capturing the attention of savvy investors with its compelling growth potential, despite facing some headwinds in its financial metrics. As a healthcare company operating in the specialty and generic drug manufacturing industry, Evolus stands out with its innovative approach to performance beauty products, prominently featuring Jeuveau, a botulinum toxin formulation, and Evolysse, a hyaluronic acid gel collection.

**Market Position and Financial Overview**

Evolus currently holds a market capitalization of $286.5 million, reflecting its position as a small-cap player in the competitive healthcare sector. Despite a challenging year, with its stock trading at $4.42, close to the lower end of its 52-week…